CA2854131C - Use of an anti-.alpha.-synuclein antibody to diagnose an elevated level of .alpha.-synuclein in the brain - Google Patents
Use of an anti-.alpha.-synuclein antibody to diagnose an elevated level of .alpha.-synuclein in the brain Download PDFInfo
- Publication number
- CA2854131C CA2854131C CA2854131A CA2854131A CA2854131C CA 2854131 C CA2854131 C CA 2854131C CA 2854131 A CA2854131 A CA 2854131A CA 2854131 A CA2854131 A CA 2854131A CA 2854131 C CA2854131 C CA 2854131C
- Authority
- CA
- Canada
- Prior art keywords
- synuclein
- alpha
- antibody
- antigen
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/385—Congenital anomalies
- G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161554924P | 2011-11-02 | 2011-11-02 | |
| US61/554,924 | 2011-11-02 | ||
| PCT/US2012/062430 WO2013066818A1 (en) | 2011-11-02 | 2012-10-29 | USE OF AN ANTI-α-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL OF α-SYNUCLEIN IN THE BRAIN |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2854131A1 CA2854131A1 (en) | 2013-05-10 |
| CA2854131C true CA2854131C (en) | 2020-07-07 |
Family
ID=48192661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2854131A Active CA2854131C (en) | 2011-11-02 | 2012-10-29 | Use of an anti-.alpha.-synuclein antibody to diagnose an elevated level of .alpha.-synuclein in the brain |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20140295465A1 (enExample) |
| EP (1) | EP2773957B1 (enExample) |
| JP (1) | JP6263473B2 (enExample) |
| KR (1) | KR102036938B1 (enExample) |
| CN (2) | CN107091931A (enExample) |
| AU (1) | AU2012332814B2 (enExample) |
| BR (1) | BR112014010664A2 (enExample) |
| CA (1) | CA2854131C (enExample) |
| EA (1) | EA034213B1 (enExample) |
| IL (1) | IL232373B (enExample) |
| MX (1) | MX356797B (enExample) |
| WO (1) | WO2013066818A1 (enExample) |
| ZA (1) | ZA201403879B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20150831T1 (hr) | 2008-12-19 | 2015-10-09 | Biogen International Neuroscience Gmbh | Humana anti-alfa- sinuklein auto-protutijela |
| PL2723379T3 (pl) | 2011-06-23 | 2019-05-31 | Biogen Int Neuroscience Gmbh | Cząsteczki wiążące przeciwko alfa-synukleinie |
| JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック， インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
| JP6273338B1 (ja) * | 2016-12-05 | 2018-01-31 | 磁量生技股▲ふん▼有限公司 | パーキンソン病からパーキンソン病認知症を特定する方法 |
| US12049493B2 (en) | 2017-01-06 | 2024-07-30 | Abl Bio Inc. | Anti-alpha-synuclein antibodies and uses thereof |
| WO2018128454A1 (ko) * | 2017-01-06 | 2018-07-12 | 에이비엘바이오 주식회사 | 항 α-SYN 항체 및 그 용도 |
| JP7136790B2 (ja) | 2017-02-17 | 2022-09-13 | ブリストル－マイヤーズ スクイブ カンパニー | アルファ－シヌクレインに対する抗体およびその使用 |
| BR112020011875A2 (pt) | 2017-12-14 | 2020-11-24 | Abl Bio Inc. | anticorpo biespecífico ao a-syn/igf1r e uso do mesmo |
| GB201803553D0 (en) | 2018-03-06 | 2018-04-18 | Univ Newcastle | Detection of pathological protein aggregation |
| WO2020009482A1 (ko) * | 2018-07-03 | 2020-01-09 | 에이비엘바이오 주식회사 | 항 알파-시누클레인 항체 및 그 용도 |
| EP3629021A1 (en) * | 2018-09-26 | 2020-04-01 | Euroimmun Medizinische Labordiagnostika AG | Diagnosis of a neuroautoimmune disease |
| KR102252879B1 (ko) * | 2019-11-15 | 2021-05-17 | 성균관대학교산학협력단 | 혈장 내 aimp2를 이용한 파킨슨 질환의 진단 방법, 이를 위한 조성물 및 이를 포함하는 키트 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| AU3117799A (en) * | 1998-03-30 | 1999-10-18 | Trustees Of The University Of Pennsylvania, The | Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders |
| CN1440420A (zh) * | 2000-07-07 | 2003-09-03 | 万能药制药公司 | 预防神经组织损伤和治疗α－共核蛋白疾病的方法 |
| GB0203446D0 (en) * | 2002-02-14 | 2002-04-03 | Univ Lancaster | Detection and/or monitoring of synuclein-related diseases |
| CA2657953A1 (en) * | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
| HUE033325T2 (en) | 2007-01-05 | 2017-11-28 | Univ Zuerich | Anti-beta-amyloid binder antibodies and their use |
| CN101308144A (zh) * | 2007-05-16 | 2008-11-19 | 首都医科大学宣武医院 | 检测受试者体液内疾病相关蛋白聚合能力的方法 |
| ES2709048T3 (es) * | 2008-04-29 | 2019-04-15 | Bioarctic Ab | Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína |
| HRP20150831T1 (hr) * | 2008-12-19 | 2015-10-09 | Biogen International Neuroscience Gmbh | Humana anti-alfa- sinuklein auto-protutijela |
| CN101692092B (zh) * | 2009-09-24 | 2013-04-10 | 首都医科大学宣武医院 | 定量检测人血清中自体α-突触核蛋白抗体的方法 |
-
2012
- 2012-10-29 MX MX2014005378A patent/MX356797B/es active IP Right Grant
- 2012-10-29 WO PCT/US2012/062430 patent/WO2013066818A1/en not_active Ceased
- 2012-10-29 CA CA2854131A patent/CA2854131C/en active Active
- 2012-10-29 EP EP12846452.6A patent/EP2773957B1/en active Active
- 2012-10-29 EA EA201490883A patent/EA034213B1/ru unknown
- 2012-10-29 US US14/355,743 patent/US20140295465A1/en not_active Abandoned
- 2012-10-29 CN CN201710252366.1A patent/CN107091931A/zh active Pending
- 2012-10-29 CN CN201280065165.6A patent/CN104040342A/zh active Pending
- 2012-10-29 AU AU2012332814A patent/AU2012332814B2/en not_active Ceased
- 2012-10-29 KR KR1020147014713A patent/KR102036938B1/ko not_active Expired - Fee Related
- 2012-10-29 JP JP2014540007A patent/JP6263473B2/ja not_active Expired - Fee Related
- 2012-10-29 BR BR112014010664A patent/BR112014010664A2/pt not_active Application Discontinuation
-
2014
- 2014-04-30 IL IL232373A patent/IL232373B/en active IP Right Grant
- 2014-05-27 ZA ZA2014/03879A patent/ZA201403879B/en unknown
-
2017
- 2017-01-19 US US15/409,671 patent/US20180011112A1/en not_active Abandoned
-
2018
- 2018-05-16 US US15/981,691 patent/US20190094245A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR102036938B1 (ko) | 2019-10-25 |
| ZA201403879B (en) | 2018-11-28 |
| CN104040342A (zh) | 2014-09-10 |
| KR20140095074A (ko) | 2014-07-31 |
| BR112014010664A2 (pt) | 2017-04-25 |
| MX2014005378A (es) | 2015-01-19 |
| CN107091931A (zh) | 2017-08-25 |
| JP6263473B2 (ja) | 2018-01-31 |
| EA201490883A1 (ru) | 2014-10-30 |
| EP2773957A1 (en) | 2014-09-10 |
| US20180011112A1 (en) | 2018-01-11 |
| CA2854131A1 (en) | 2013-05-10 |
| EA034213B1 (ru) | 2020-01-17 |
| US20190094245A1 (en) | 2019-03-28 |
| WO2013066818A1 (en) | 2013-05-10 |
| MX356797B (es) | 2018-06-14 |
| EP2773957A4 (en) | 2015-06-24 |
| AU2012332814B2 (en) | 2017-12-14 |
| AU2012332814A1 (en) | 2014-06-12 |
| IL232373B (en) | 2018-08-30 |
| EP2773957B1 (en) | 2017-11-29 |
| HK1201585A1 (en) | 2015-09-04 |
| NZ625217A (en) | 2016-07-29 |
| JP2014533357A (ja) | 2014-12-11 |
| IL232373A0 (en) | 2014-06-30 |
| US20140295465A1 (en) | 2014-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012332814B2 (en) | Use of an anti-alpha-synuclein antibody to diagnose an elevated level of alpha-synuclein in the brain | |
| ES2773961T3 (es) | Uso de moléculas de unión a semaforina-4D para el tratamiento de trastornos neurodegenerativos | |
| US9849165B2 (en) | Oligomer-specific amyloid beta epitope and antibodies | |
| JP7626416B2 (ja) | 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法 | |
| JP2019108359A (ja) | アテローム性動脈硬化の処置のためのセマフォリン−４ｄ結合分子の使用 | |
| CA2894178A1 (en) | A method of reducing brain amyloid plaques using anti-a.beta. antibodies | |
| TW201542589A (zh) | 偵測人類ｐｅｒｉｏｓｔｉｎ之新穎分析法 | |
| HK1201585B (en) | Use of an anti-alpha-synuclein antibody to diagnose an elevated level of alpha-synuclein in the brain | |
| NZ625217B2 (en) | Use of an anti-?-synuclein antibody to diagnose an elevated level of ?-synuclein in the brain | |
| AU2013205000B2 (en) | Oligomer-specific amyloid beta epitope and antibodies | |
| HK1231887A1 (en) | Oligomer-specific amyloid beta epitope and antibodies | |
| HK1185350B (en) | Oligomer-specific amyloid beta epitope and antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170906 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251008 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251224 |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20260120 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260120 |